Top

Published in:

Open Access 01-12-2021 | Cytostatic Therapy | Research article

Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers

Authors: Maureen Bernadach, Michel Lapeyre, Anne-Françoise Dillies, Jessica Miroir, Melanie Casile, Juliette Moreau, Ioana Molnar, Angeline Ginzac, Nathalie Pham-Dang, Nicolas Saroul, Xavier Durando, Julian Biau

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

The rate of toxic deaths related to induction chemotherapy in the treatment of locally advanced head and neck cancers is unacceptable and calls into question this therapeutic strategy, which is however highly effective in terms of rate and speed of response. The purpose of the study was to investigate predictive factors of toxicity of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) in locally advanced head and neck cancers (LAHNC).

Methods

Between June 2009 and December 2017, 113 patients treated consecutively with TPF were included retrospectively. Patients were receiving induction chemotherapy for either an inoperable cancer or laryngeal preservation. For inoperable cancer, induction chemotherapy was proposed to patients presenting either a large tumor with strong symptoms (dyspnea, dysphagia, pain) or a tumor with rapid progression. Risk factors were chosen among the initial patient and tumour characteristics and chemotherapy modalities.

Results

Eighty-nine patients (79%) were male; the median age was 58 years [32–71]. Sixty-nine (61%) patients were treated for inoperable cancer and 44 (39%) for laryngeal preservation. 45% had stage IVa cancer, 28% stage III and 25% stage IVb. Sixty percent of patients had a partial response after TPF, 22% had a complete response, 12% were stable, 5% were progressing, and 1% had a discordant response. Thirty-four patients (30%) received enteral feeding during induction chemotherapy with TPF. The possibility of oral feeding without a tube was predictive of a better response (p = 0.003). Seven (6%) patients died during TPF. There was an increased risk of death with preexisting liver dysfunction (liver dysmorphia on imaging or decrease prothrombin rate) (p = 0.032). There was an increased risk of grade ≥ 3 infection if an enteral feeding occurred during the period of induction chemotherapy (p = 0.03).

Conclusions

TPF induction chemotherapy had an 82% objective response rate with 6% toxic deaths. Nutritional status and the presence of hepatic dysfunction are significant risk factors to be taken into account in therapeutic decisions.

Available only for authorised users

Schwarzinger M, Huguet F, Témam S, Pointreau Y, Bec M, Even C, et al. PO-120: head and neck cancers are associated with poor EQ-5D-related utility in France (EPICORL study). Radiother Oncol. 2017;122:57. https://doi.org/10.1016/S0167-8140(17)30254-2.CrossRef

Hawkins NV. Panel discussion on glottic tumors. VIII. The treatment of glottic carcinoma: an analysis of 800 cases. Laryngoscope. 2009;85(9):1485–93.CrossRef

Jesse RH. The evaluation of treatment of patients with extensive squamous cancer of the vocal cords. Laryngoscope. 1975;85(9):1424–9. https://doi.org/10.1288/00005537-197509000-00002.CrossRefPubMed

Harwood AR, Rawlinson E. The quality of life of patients following treatment for laryngeal cancer. Int J Radiat Oncol Biol Phys. 1983;9(3):335–8. https://doi.org/10.1016/0360-3016(83)90292-4.CrossRefPubMed

McNeil BJ, Weichselbaum R, Pauker SG. Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med. 1981;305(17):982–7. https://doi.org/10.1056/NEJM198110223051704.CrossRefPubMed

Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324(24):1685–90.

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78. https://doi.org/10.1056/NEJMoa053422.CrossRefPubMed

Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and Docetaxel in Unresectable head and neck Cancer. N Engl J Med. 2007;357(17):1695–704. https://doi.org/10.1056/NEJMoa071028.CrossRefPubMed

Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with Docetaxel in head and neck Cancer. N Engl J Med. 2007;357(17):1705–15. https://doi.org/10.1056/NEJMoa070956.CrossRefPubMed

10.

Pignon J-P, le Maître A, Maillard E, Bourhis J. MACH-NC collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2009;92(1):4–14. https://doi.org/10.1016/j.radonc.2009.04.014.CrossRef

11.

Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Hernandez JJC, et al. Taxane-Cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck Cancer group. J Clin Oncol. 2013;31(23):2854–60. https://doi.org/10.1200/JCO.2012.47.7802.CrossRefPubMed

12.

Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck Cancer. Lancet Lond Engl. 2000;355(9208):949–55. https://doi.org/10.1016/S0140-6736(00)90011-4.CrossRef

13.

Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, et al. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2009;20(5):921–7. https://doi.org/10.1093/annonc/mdn752.CrossRef

14.

Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2011;100(1):33–40. https://doi.org/10.1016/j.radonc.2011.05.036.CrossRef

15.

Richard JM, Sancho-Garnier H, Pessey JJ, Luboinski B, Lefebvre JL, Dehesdin D, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. 1998;34(3):224–8. https://doi.org/10.1016/S1368-8375(97)00090-0.CrossRefPubMed

16.

Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal Cancer. N Engl J Med. 2003;349(22):2091–8. https://doi.org/10.1056/NEJMoa031317.CrossRefPubMed

17.

Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, et al. Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy. J Natl Cancer Inst. 2009; Available from: http://jnci.oxfordjournals.org/content/early/2009/01/27/jnci.djn460. [cited 2016 Feb 7].

18.

Lefebvre J-L, Andry G, Chevalier D, Luboinski B, Collette L, Traissac L, et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol. 2012;23(10):2708–14. https://doi.org/10.1093/annonc/mds065.CrossRefPubMedPubMedCentral

19.

Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101(7):498–506. https://doi.org/10.1093/jnci/djp007.CrossRefPubMed

20.

Paccagnella A, Ghi MG, Loreggian L, Buffoli A, Koussis H, Mione CA, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol. 2010;21(7):1515–22. https://doi.org/10.1093/annonc/mdp573.CrossRefPubMed

21.

Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14(3):257–64. https://doi.org/10.1016/S1470-2045(13)70011-1.CrossRefPubMed

22.

Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2014;25(1):216–25. https://doi.org/10.1093/annonc/mdt461.CrossRef

23.

Takácsi-Nagy Z, Hitre E, Remenár É, Oberna F, Polgár C, Major T, et al. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III–IV unresectable head and neck cancer. Strahlenther Onkol. 2015;191(8):635–41. https://doi.org/10.1007/s00066-015-0829-z.CrossRefPubMed

24.

Budach W, Bölke E, Kammers K, Gerber PA, Orth K, Gripp S, et al. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): a meta-analysis of randomized trials. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2016;118(2):238–43. https://doi.org/10.1016/j.radonc.2015.10.014.CrossRef

25.

Cohen EEW, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck Cancer. J Clin Oncol. 2014;32(25):2735–43. https://doi.org/10.1200/JCO.2013.54.6309.CrossRefPubMedPubMedCentral

26.

Fulcher CD, Haigentz M, Ow TJ. AHNS series: do you know your guidelines? Principles of treatment for locally advanced or Unresectable head and neck squamous cell carcinoma. Head Neck. 2018;40(4):676–86. https://doi.org/10.1002/hed.25025.CrossRefPubMed

27.

Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, et al. Induction chemotherapy followed by Cetuximab radiotherapy is not superior to concurrent Chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 phase III randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(31):3077–83. https://doi.org/10.1200/JCO.2017.76.2591.CrossRef

28.

Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing Cisplatin plus fluorouracil to paclitaxel, Cisplatin, and fluorouracil induction chemotherapy followed by Chemoradiotherapy in locally advanced head and neck Cancer. J Clin Oncol. 2005;23(34):8636–45. https://doi.org/10.1200/JCO.2004.00.1990.CrossRefPubMed

29.

Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either Chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013;31(7):853–9. https://doi.org/10.1200/JCO.2012.42.3988.CrossRefPubMed

30.

Geoffrois L, Martin L, Garaud P, De Raucourt D, Miny J, Maingon P, et al. Induction docetaxel platinum 5-FU (TPF) followed by cetuximab-radiotherapy (cetux-RT) versus concurrent chemo-radiotherapy (CT/RT) in patients with N2b/c-N3 non operated stage III-IV squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC 2007–02 phase III randomized trial. J Clin Oncol. 2016;34(15_suppl):6000.CrossRef

31.

Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecà C, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(9):2206–12. https://doi.org/10.1093/annonc/mdx299.CrossRef

32.

Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(28):3199–212. https://doi.org/10.1200/JCO.2015.62.3488.CrossRef

33.

The Comprehensive R Archive Network. Available from: https://cran.r-project.org/. [cited 2020 Jan 30]

34.

Pressoir M, Desné S, Berchery D, Rossignol G, Poiree B, Meslier M, et al. Prevalence, risk factors and clinical implications of malnutrition in French comprehensive Cancer Centres. Br J Cancer. 2010;102(6):966–71. https://doi.org/10.1038/sj.bjc.6605578.CrossRefPubMedPubMedCentral

35.

Jager-Wittenaar H, Dijkstra PU, Vissink A, van der Laan BFAM, van Oort RP, Roodenburg JLN. Critical weight loss in head and neck cancer—prevalence and risk factors at diagnosis: an explorative study. Support Care Cancer. 2007;15(9):1045–50. https://doi.org/10.1007/s00520-006-0212-9.CrossRefPubMed

36.

Bressan V, Bagnasco A, Aleo G, Catania G, Zanini MP, Timmins F, et al. The life experience of nutrition impact symptoms during treatment for head and neck cancer patients: a systematic review and meta-synthesis. Support Care Cancer. 2017;25(5):1699–712. https://doi.org/10.1007/s00520-017-3618-7.CrossRefPubMed

37.

Fayette J, Fontaine-Delaruelle C, Ambrun A, Daveau C, Poupart M, Ramade A, et al. Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients. Oncotarget. 2016;7(24):37297–304. https://doi.org/10.18632/oncotarget.8934.CrossRefPubMedPubMedCentral

38.

Guigay J, Fayette J, Dillies AF, Sire C, Kerger JN, Tennevet I, et al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(9):1941–7. https://doi.org/10.1093/annonc/mdv268.CrossRef

39.

2019 ASCO: Final Analysis of KEYNOTE-048: First-Line Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - The ASCO Post. Available from: https://www.ascopost.com/News/60093. [cited 2019 Oct 28]

Title: Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers
Authors: Maureen Bernadach
Michel Lapeyre
Anne-Françoise Dillies
Jessica Miroir
Melanie Casile
Juliette Moreau
Ioana Molnar
Angeline Ginzac
Nathalie Pham-Dang
Nicolas Saroul
Xavier Durando
Julian Biau
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08128-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

A stable gene set for prediction of prognosis and efficacy of chemotherapy in gastric cancer

Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients

A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules

FOXD1 regulates cell division in clear cell renal cell carcinoma

Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model

MiR-105-3p acts as an oncogene to promote the proliferation and metastasis of breast cancer cells by targeting GOLIM4

Keynote webinar | Spotlight on antibody–drug conjugates in cancer